Teva subpoenaed by SEC investigating Latin American bribes
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has been subpoenaed by the US SEC and has begun an internal investigation into "certain business practices which may have FCPA implications", the company revealed in a note buried in its latest quarterly results filing with the US Securities and Exchange Commission.
You may also be interested in...
Big Pharma’s Aging Antibodies Cling To Their Crowns
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis To Pay $9.7bn For The Medicines Company
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Need a specific report? 1000+ reports available
Buy Reports